Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American Society of Hematology (ASH).

26 Apr 2013

Roundup: Calif. health care cuts attract opponents; Health law means fewer hours for Va. community college instructors

In the health care world, there's not a whole lot that insurers, doctors and union workers all agree on. But a new coalition of powerful Capitol players from all three groups is hoping to reverse recent budget cuts, pushed by Gov. Jerry Brown, to those who provide care to the poorest Californians.

25 Apr 2013

Research project to identify mechanisms underlying effects of cancer drug interferon-α

The immune system plays a decisive role in the fight against tumor cells. However, when tumor cells themselves prevent activation of the immune system, the immune system fails to destroy cancer cells.

24 Apr 2013

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Pharmacyclics, Inc. announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma, (RESONATE) was achieved on April 3, 2013.

23 Apr 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

New chemical compound offers a promising step for creating potential anti-cancer agents

Scientists at the Walter and Eliza Hall Institute and their collaborators have tailor-made a new chemical compound that blocks a protein that has been linked to poor responses to treatment in cancer patients.

22 Apr 2013

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

A researcher at The Feinstein Institute for Medical Research has discovered additional mechanical properties of articular cartilage, a protective cartilage on the ends of bones that wears down over time, resulting in the development of osteoarthritis.

20 Apr 2013

Hookah smoking is equally harmful like cigarettes

Smoking tobacco through a hookah is a pastime gaining popularity among the college crowd, but many of them mistakenly believe that using the fragrant water pipe is less harmful than smoking cigarettes.

19 Apr 2013

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

Patients from ethnic minority and mixed-racial backgrounds are less likely to receive a lifesaving bone marrow transplant than Caucasian patients with the same disease due to lack of matching donors, according to the National Marrow Donor Program.

19 Apr 2013

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

Inovio Pharmaceuticals, Inc. announced today that its SynCon universal H1N1 influenza vaccine generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain.

19 Apr 2013

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins.

18 Apr 2013

Researchers find potential new genetic chemotherapy approach for cancer treatment

Researchers at The Jackson Laboratory have identified a molecule that prevents repair of some cancer cells, providing a potential new "genetic chemotherapy" approach to cancer treatment that could significantly reduce side effects and the development of treatment resistance compared with traditional chemotherapy.

18 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

New partnership to introduce advanced genetic testing technologies to Turkey

BGI Health and ACIBADEM Healthcare Group Genetic Diagnostic Center in cooperation with Genoks Company Molecular Biology, signed a Memorandum of Understanding for jointly introducing the advanced genetic testing technologies to Turkey and improving Turkish reproductive healthcare.

17 Apr 2013

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Recently, doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment.

16 Apr 2013

Michigan's first cardio-oncology clinic launched to prevent heart problems

As cancer therapy becomes more effective and the number of cancer survivors increases, doctors are faced with a new challenge: ensuring patients have a healthy heart to enjoy the rest of their lives.

16 Apr 2013

Protein helps leukemia cells avoid effects of chemotherapy by appearing dormant

A new study on how the progression of acute lymphocytic leukemia is influenced by the bone marrow environment has demonstrated for the first time that targeting a specialized protein known as osteopontin may be an effective strategy to increase the efficacy of chemotherapy in patients with this type of blood cancer.

16 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

$Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients$

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.

11 Apr 2013

Leukemia News and Research

Further Reading

Increasing unsustainable prices for leukemia drugs represent larger issue across all cancers

Roundup: Calif. health care cuts attract opponents; Health law means fewer hours for Va. community college instructors

Research project to identify mechanisms underlying effects of cancer drug interferon-α

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

Enrollment for Pharmacyclics' Phase III study using ibrutinib in CLL patients completed

Study identifies potential drug targets that interfere with cancer metabolism

New chemical compound offers a promising step for creating potential anti-cancer agents

Researcher discovers additional mechanical properties of articular cartilage result in osteoarthritis

Hookah smoking is equally harmful like cigarettes

SCCA pioneers new transplant procedures to reduce need for matching bone marrow donors

SynCon universal H1N1 influenza vaccine generates protective antibody levels in phase 1 study

New pre-clinical study suggests novel drug combination therapy for leukemia treatment

Researchers find potential new genetic chemotherapy approach for cancer treatment

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

New partnership to introduce advanced genetic testing technologies to Turkey

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Michigan's first cardio-oncology clinic launched to prevent heart problems

Protein helps leukemia cells avoid effects of chemotherapy by appearing dormant

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Pharmacyclics presents positive results of ibrutinib Phase II trial in untreated, relapsed and refractory CLL patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News